Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A study shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United States Food and Drug ...

Researchers at UT Southwestern Medical Center found that tenecteplase, a newer drug, is just as safe and effective as ...

The drug will only be made available on the NHS for patients whose medical or surgical treatment for endometriosis has failed ...

The measure, which passed with bipartisan support and minor changes, now heads back to the House. It is just the second ...

The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...

Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.

UVA School of Medicine emeritus professor Dr. Frederick G. Hayden helped design the trial and presented the results Wednesday ...

PharmaTher (PHRRF) has received an Amendment Acknowledgement Letter from the U.S. Food and Drug Administration for its New Drug Application for ...

The FDA’s latest draft guidance on accelerated approval for new drugs, “Expedited Program for Serious Conditions—Accelerated Approval of Drugs and Biologics,” is a game-changer for biopharmaceutical ...

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.